Given our finding that condensate-competent TIA1 is a potent brake on glycolysis, we asked whether BCG could exploit the same axis to impose a metabolic ‘checkpoint’ on bladder cancer cells, thereby creating a micro-environment conducive to subsequent CD8+-T-cell attack. The gene discussed is TIA1; the disease is urinary bladder cancer.